References
- Aghaei M, Panjehpour M, Karami-Tehrani F, et al (2011). Molecular mechanisms of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway. J Cancer Res Clin Oncol, 137, 1511-23. https://doi.org/10.1007/s00432-011-1031-z
- Baade PD, Yu XQ, Smith DP, et al (2015). Geographic disparities in prostate cancer outcomes--review of international patterns. Asian Pac J Cancer Prev, 16, 1259-75. https://doi.org/10.7314/APJCP.2015.16.3.1259
- Bachmann HS, Heukamp LC, Schmitz KJ, et al (2011). Regulatory BCL2 promoter polymorphism (-938C>A). is associated with adverse outcome in patients with prostate carcinoma. Int J Cancer, 129, 2390-9. https://doi.org/10.1002/ijc.25904
- Bantis A, Giannopoulos A, Gonidi M, et al (2004). Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value. Cytopathology, 15, 25-31. https://doi.org/10.1046/j.0956-5507.2003.00090.x
- Bashir MN (2015). Epidemiology of Prostate Cancer. Asian Pac J Cancer Prev, 16, 5137-41. https://doi.org/10.7314/APJCP.2015.16.13.5137
- Bauer JJ, Sesterhenn IA, Mostofi FK, et al (1996). Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol, 156, 1511-6. https://doi.org/10.1016/S0022-5347(01)65641-6
- Bensalah K, Lotan Y, Karam JA et al (2008). New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis, 11, 112-20. https://doi.org/10.1038/sj.pcan.4501026
- Berney DM, Gopalan A, Kudahetti S, et al (2009). Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer, 100, 888-93. https://doi.org/10.1038/sj.bjc.6604951
- Bostrom PJ, Bjartell AS, Catto JW, et al (2015). Genomic predictors of outcome in prostate cancer. Eur Urol, 68, 1033-44. https://doi.org/10.1016/j.eururo.2015.04.008
- Calvo BF, Levine AM, Marcos M, et al (2003). Human epidermal receptor-2 expression in prostate cancer. Clin Cancer Res, 9, 1087-97.
- Chuang AY, DeMarzo AM, Veltri RW, et al (2007). Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol, 31, 1246-55. https://doi.org/10.1097/PAS.0b013e31802f5d33
- Concato J, Jain D, Uchio E, et al (2009). Molecular markers and death from prostate cancer. Ann Intern Med, 150, 595-603. https://doi.org/10.7326/0003-4819-150-9-200905050-00005
- Daniyal M, Siddiqui ZA, Akram M, et al (2014). Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev, 15, 9575-8. https://doi.org/10.7314/APJCP.2014.15.22.9575
- Esfahani M, Ataei N, Panjehpour M (2015). Biomarkers for Evaluation of Prostate Cancer Prognosis. Asian Pac J Cancer Prev, 16, 2601-11. https://doi.org/10.7314/APJCP.2015.16.7.2601
- Fonseca GN, Srougi M, Leite KR, et al (2004). The role of HER2/neu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma. Sao Paulo Med J, 122, 124-7. https://doi.org/10.1590/S1516-31802004000300009
- Freedland SJ, deGregorio F, Sacoolidge JC, et al (2003). Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J Urol, 169, 1325-30. https://doi.org/10.1097/01.ju.0000054004.08958.f3
- Globocan (2012). Assessed the 23rd April 2016, http://globocan.iarc.fr/Default.aspx.
- Goto T, Nguyen BP, Nakano M, et al (2008). Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population. Urol, 72, 167-71. https://doi.org/10.1016/j.urology.2007.11.003
- Ho CC, Seong PK, Zainuddin ZM, et al (2013). Retrospective study of predictors of bone metastasis in prostate cancer cases. Asian Pac J Cancer Prev, 14, 3289-92. https://doi.org/10.7314/APJCP.2013.14.5.3289
- Hughes C, Murphy A, Martin C, et al (2005). Molecular pathology of prostate cancer. J Clin Pathol, 58, 673-84. https://doi.org/10.1136/jcp.2002.003954
- Inoue T, Segawa T, Shiraishi T, et al (2005). Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urol, 66, 332-7. https://doi.org/10.1016/j.urology.2005.02.028
- Isharwal S, Miller MC, Epstein JI, et al (2008). Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy. Int J Cancer, 123, 2636-43. https://doi.org/10.1002/ijc.23838
- Kluth M, Harasimowicz S, Burkhardt L, et al (2014). Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer. Int J Cancer, 135, 1369-80. https://doi.org/10.1002/ijc.28784
- Kuczyk MA, Serth J, Bokemeyer C, et al (1998). The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy. Eur J Cancer, 34, 679-86. https://doi.org/10.1016/S0959-8049(97)10112-5
- Larkin SE, Holmes S, Cree IA, et al (2012). Identification of markers of prostate cancer progression using candidate gene expression. Br J Cancer, 106, 157-65. https://doi.org/10.1038/bjc.2011.490
-
Lazari P, Poulias H, Gakiopoulou H, et al (2013). Differential immunohistochemical expression of CD44s, E-cadherin and
${\beta}$ -catenin among hyperplastic and neoplastic lesions of the prostate gland. Urol Int, 90, 109-16. https://doi.org/10.1159/000345057 - Missaoui N, Trabelsi A, Parkin DM, et al (2010). Trends in the incidence of cancer in the Sousse region, Tunisia, 1993-2006. Int J Cancer, 127, 2669-77. https://doi.org/10.1002/ijc.25490
- Maru N, Ohori M, Kattan MW, et al (2001). Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Hum Pathol, 32, 828-33. https://doi.org/10.1053/hupa.2001.26456
- Molinie V, Beuzeboc P, Mahjoub WK et al (2008). Molecular biology and prostate cancer: evolution or revolution? Ann Pathol, 28, 354-62. https://doi.org/10.1016/j.annpat.2008.07.004
- Molinie V (2008). Gleason's score: update in 2008. Ann Pathol, 28, 350-53. https://doi.org/10.1016/j.annpat.2008.07.006
- Quinn DI, Henshall SM, Sutherland RL (2005). Molecular markers of prostate cancer outcome. Eur J Cancer, 41, 858-87. https://doi.org/10.1016/j.ejca.2004.12.035
- Ramirez ML, Nelson EC, Evans CP (2008). Beyond prostate-specific antigen: alternate serum markers. Prostate Cancer, 11, 216-29. https://doi.org/10.1038/pcan.2008.2
- Ribal MJ, Fernandez PL, Lopez-Guillermo A, et al (2003). Low p27 expression predicts biochemical relapse after radical prostatectomy in patients with clinically localised prostate cancer. Anticancer Res, 23, 5101-6.
- Salomon L, Azria D, Bastide C, et al (2010). Recommendations Onco-Urology 2010: Prostate cancer. Prog Urol, 20, 217-51. https://doi.org/10.1016/S1166-7087(10)70042-7
- Sirma H, Broemel M, Stumm L, et al (2013). Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis. Oncol Lett, 6, 1245-52. https://doi.org/10.3892/ol.2013.1563
- Rubio J, Ramos D, Lopez-Guerrero JA, et al (2005). Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol, 48, 745-51. https://doi.org/10.1016/j.eururo.2005.06.014
- Umbas R, Isaacs WB, Bringuier PP, et al (1994). Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res, 54, 3929-33.
- Van Dong H, Lee AH, Nga NH, et al (2014). Epidemiology and prevention of prostate cancer in Vietnam. Asian Pac J Cancer Prev, 15, 9747-51. https://doi.org/10.7314/APJCP.2014.15.22.9747
- Verhoven B, Yan Y, Ritter M, et al (2013). Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG). 94-08. Int J Radiat Oncol Biol Phys, 86, 317-23. https://doi.org/10.1016/j.ijrobp.2013.01.016
- Wang K, Peng HL, Li LK (2012). Prognostic value of vascular endothelial growth factor expression in patients with prostate cancer: a systematic review with meta-analysis. Asian Pac J Cancer Prev, 13, 5665-9. https://doi.org/10.7314/APJCP.2012.13.11.5665
- Wolff AC, Hammond ME, Hicks DG, et al (2013). Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol, 31, 3997-4013. https://doi.org/10.1200/JCO.2013.50.9984
- Yamashita K, Denno K, Ueda T, et al (1993). Prognostic significance of bone metastases in patients with metastatic prostate cancer. Cancer, 71, 1297-302. https://doi.org/10.1002/1097-0142(19930215)71:4<1297::AID-CNCR2820710421>3.0.CO;2-S
- Yang RM, Naitoh J, Murphy M, et al (1998). Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol, 159, 941-5. https://doi.org/10.1016/S0022-5347(01)63776-5
- Zahir ST, Tafti HF, Rahmani K (2014). Overexpression of HER-2/neu in patients with prostatic adenocarcinoma. Asian Pac J Cancer Prev, 15, 6425-8. https://doi.org/10.7314/APJCP.2014.15.15.6425
- Zhang YF, Guan YB, Yang B, et al (2011). Prognostic value of Her-2/neu and clinicopathologic factors for evaluating progression and disease-specific death in Chinese men with prostate cancer. Chin Med J (Engl), 124, 4345-9.
- Zhigang Z, Wenlv S (2004). Prostate stem cell antigen (PSCA). expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World J Surg Oncol, 2, 13. https://doi.org/10.1186/1477-7819-2-13